BioSpace News Archive

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL)

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company’s annual meeting of shareholders.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Thursd

Ichnos Sciences Inc., a fully integrated, global biotechnology company developing potentially transformative biologic therapies that harness the immune system to treat cancer, is pleased to announce that Alessandro Riva , M.D., Chief Executive Officer, will be presenting today at the virtual 39 th Annual J.P. Morgan Healthcare Conferen

Novel test supports vaccine development studies critical to aiding researchers in understanding immunity levels and disease progression

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021. The presentations will co

Sharps Compliance Corp. announced that it will release its second quarter 2021 results for the period ended December 31, 2020, before the opening of the financial markets on Thursday, January 28, 2021.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter has sold media to two top research medical centers, one in New York City and the other in Boston, Massachusetts

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson’s Disease (PD).

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.